Expression of p53 & epidermal growth factor receptor in glioblastoma

被引:7
作者
Karnam, Sameera
Kottu, Radhika [1 ]
Chowhan, Amit Kumar
Bodepati, Prasad Chandramouleswara
机构
[1] Sri Venkateswara Inst Med Sci, Dept Pathol, Alipiri Rd, Tirupati 517507, Andhra Pradesh, India
关键词
Epidermal growth factor receptor; glioblastoma; immunohistochemistry; p53; ASTROCYTOMA PROGRESSION; GENE AMPLIFICATION; MULTIFORME; MUTATIONS; PROTEIN; EGFR; HETEROZYGOSITY; CLASSIFICATION; POPULATION; PATHWAYS;
D O I
10.4103/ijmr.IJMR_1179_15
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopathologically, primary and secondary GBs are indistinguishable. The aim of this investigation was to study the immunohistochemical (IHC) expression of p53 and epidermal growth factor receptor (EGFR) in GB with the objective of categorizing the morphological variants of GB into primary and secondary based on the presence of low-grade areas and knowing the variable expression of p53 and EGFR in primary and secondary GB. Methods: A total of 28 patients with GB were studied and categorized into primary and secondary based on the presence of low-grade areas, i.e. discernible astrocytic morphology, gemistocyte and oligodendroglia. Tumours with the presence of combination of the above features or any one of the above features were taken as secondary GB, whereas tumours with highly pleomorphic areas were considered as primary GB. IHC was done on the representative tissue blocks for p53 and EGFR. Results: Majority of the patients were in the fifth and sixth decades of life with a mean age of 46.96 +/- 13 yr with male preponderance (male:female 2.5:1). Mean age of presentation was 48.93 +/- 12 yr in primary and 44.69 +/- 15 yr in secondary GB. All cases of GB were classified into primary (53.57%) and secondary (46.43%) based on morphology. EGFR was more frequently expressed than p53. Based on IHC, 50 per cent of cases were classified into primary, three per cent into secondary and 47 per cent as unclassified. Interpretation & conclusions: Histopathological features, i.e. presence of low-grade areas, may play a role in classifying GB into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary.
引用
收藏
页码:738 / 745
页数:8
相关论文
共 50 条
  • [31] Prognostic relevance of p53 protein expression in glioblastoma
    Birner, P
    Piribauer, M
    Fischer, I
    Gatterbauer, B
    Marosi, C
    Ungersböck, K
    Rössler, K
    Budka, H
    Hainfellner, JA
    ONCOLOGY REPORTS, 2002, 9 (04) : 703 - 707
  • [32] Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma
    B. Kalman
    E. Szep
    F. Garzuly
    D. E. Post
    NeuroMolecular Medicine, 2013, 15 : 420 - 434
  • [33] Epidermal growth factor receptor targeting and challenges in glioblastoma
    Thorne, Amy Haseley
    Zanca, Ciro
    Furnari, Frank
    NEURO-ONCOLOGY, 2016, 18 (07) : 914 - 918
  • [34] Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma
    Kalman, B.
    Szep, E.
    Garzuly, F.
    Post, D. E.
    NEUROMOLECULAR MEDICINE, 2013, 15 (02) : 420 - 434
  • [35] Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma
    Idbaih, A.
    Aimard, J.
    Boisselier, B.
    Marie, Y.
    Paris, S.
    Criniere, E.
    Silva, R. Carvalho
    Laigle-Donadey, F.
    Rousseau, A.
    Mokhtari, K.
    Thillet, J.
    Sanson, M.
    Hoang-Xuan, K.
    Delattre, J. -Y.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 (02) : 208 - 213
  • [36] Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry
    Lee, Minju
    Kang, So Young
    Suh, Yeon-Lim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (08) : 589 - 598
  • [37] EXPRESSION AND CLINICAL SIGNIFICANCE OF P53, O6-METHYLGUANINE-DNA METHYLTRANSFERASE AND EPIDERMAL GROWTH FACTOR RECEPTOR IN GLIOMA
    Fu, X. R.
    Sun, Z. C.
    Chang, Y.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2015, 29 (04) : 853 - 858
  • [38] Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles
    Hussein, Mahmoud R.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 87 (01) : 63 - 69
  • [39] Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan
    Ali, Syed Muhammad Adnan
    Shamim, Muhammad Shahzad
    Enam, Syed Ather
    Ahmad, Zubair
    Adnan, Yumna
    Farooqui, Hasnain Ahmed
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [40] Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan
    Ali, Syed Muhammad Adnan
    Shamim, Muhammad Shahzad
    Enam, Syed Ather
    Ahmad, Zubair
    Adnan, Yumna
    Farooqui, Hasnain Ahmed
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16